cerebrospinal fluid

People with multiple sclerosis (MS) have higher amounts of mitochondrial DNA in their spinal fluid, which surrounds the brain and spinal cord, than do their healthy counterparts, a small study found. Mitochondria are small cellular organelles that produce most of the energy needed to power cells. These cell powerhouses…

Individuals with primary progressive multiple sclerosis (PPMS) have significantly higher concentrations of specific inflammation biomarkers in their spinal fluid than healthy people, an exploratory study shows. For most biomarkers, levels in PPMS patients were comparable to or lower than those seen in people with relapsing-remitting multiple sclerosis (RRMS).

Labcorp has launched a widely accessible test that measures the levels of neurofilament light chain (NfL), a biomarker of nerve damage, to screen for signs of neurodegenerative diseases such as multiple sclerosis (MS). The test is performed on a standard blood sample taken at a hospital, at the…

The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with multiple sclerosis (MS). That finding from a small study indicates high levels of these antinuclear antibodies were correlated with relapse status and ongoing inflammation in MS. The study, “Antinuclear…

Multiple sclerosis (MS) patients with fatigue have significantly lower levels of amyloid precursor protein (APP) — a molecule involved in nerve cell function — in the cerebrospinal fluid (CSF) relative both to those without this common symptom and healthy people, a study shows. The CSF is the liquid…

People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not only furthers our understanding of the role of gut-brain communication in neurodegenerative disease progression, but also provides a potential…

There is no link between serum vitamin D levels and the age at which an individual develops the first symptoms of multiple sclerosis (MS), a new observational study suggests. However, a link was found between cerebrospinal fluid antibody levels, serum vitamin D levels, and the age at first MS…

High levels of kappa-free light chains, or kappa-FLC, in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — may help identify people with clinically isolated syndrome (CIS) who will progress sooner to multiple sclerosis (MS), a study reports. Overall, those with a high…

T-cells in the fluid around the brain share a large percentage of receptors among different multiple sclerosis (MS) patients, a new report suggests. Better understanding the diversity of T-cell receptors in MS, and how these cells vary in different parts of the body, could be useful in understanding the…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. Go here to see all the latest stories from the conference. Factors in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord change with age and can affect…

The levels of KIF5A protein are elevated in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of people with progressive multiple sclerosis (MS) and, further, are correlated with disease progression measures in patients with relapsing-remitting MS (RRMS), a new study shows. These…

People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

Immune B-cells are more abundant and have a pro-inflammatory profile in the cerebrospinal fluid (CSF), the fluid that bathes the central nervous system,  compared to blood in people with relapsing-remitting multiple sclerosis (RRMS), a study reports. The results suggest that therapeutic strategies targeting the CSF B-cells could constitute a…

A new tiny sensor is able to detect antibodies against myelin, the protective coating of nerve cell axons whose destruction is a hallmark of multiple sclerosis (MS), potentially allowing for a diagnosis in early disease stages, researchers report. It also offers the possibility of distinguishing multiple sclerosis from neuromyelitis optica, a…

A bone marrow transplant can remove the majority of overactive immune T cells from the central nervous system (CNS) in patients with active relapsing-remitting multiple sclerosis (RRMS), allowing the body to replace them with healthy ones, a study has found. This opens up new treatment avenues to…

People with multiple sclerosis (MS) have a more diverse set of immune cells in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, but no such diversity is seen in their blood, a study reports. Instead, MS causes changes in the activation of immune cells in…

Endothelin-1 (ET-1) — a molecule with potent blood vessel-narrowing (vasoconstrictive) properties — may be used as a biomarker of severity for optic neuritis in people with multiple sclerosis (MS), a small Italian study suggests. The molecule also may be a potential indicator of patients’ failure to recover…

Careful profiling of inflammatory markers in cerebrospinal fluid (CSF) of multiple sclerosis patients, coupled with standard exams and scans, helps in understanding disease evolution and treatment response, a case report suggests. It followed a relapsing-remitting multiple sclerosis (RRMS) patient whose inflammatory markers in the CSF remained high over time, and…

The cerebrospinal fluid (CSF) of people with progressive multiple sclerosis (MS) contains elevated levels of specific fatty molecules that disrupt the energy “powerhouses” of nerve cells, and appear to underlie the neurodegeneration seen on brain scans of these patients, a study reveals. The research, which compared the CSF…

A method based on cerebrospinal fluid measurements and magnetic resonance imaging (MRI) can aid in stratifying patients with multiple sclerosis (MS) at the time of diagnosis, which may help identify a tailored therapeutic approach for each patient from early disease stages. The data was presented by Roberta Magliozzi, from…

Lymphatic vessels, the “roads” that work to clear waste material from the brain, can also carry messages that direct immune system attacks against myelin, promoting the onset of multiple sclerosis (MS), new study shows. While the identity of these messages remains unknown, the findings suggest that blocking these signals could…

A meta-analysis of 13 case-control studies shows that the levels of the protein neurofilament light chain (NFL) are significantly higher in both the cerebrospinal fluid and blood of multiple sclerosis (MS) patients, compared to healthy controls. This finding adds to previous evidence supporting the usefulness of NFL as a…

Cerebrospinal fluid of progressive multiple sclerosis (MS) patients may carry lower levels of cell-free mitochondrial DNA, according to a team of researchers who say this may be a sign of neurodegeneration among these patients. The study “Cell-free mitochondrial DNA in progressive multiple sclerosis” was published in the journal Mitochondrion.

Atrophy (shrinkage) of brain lesions correlates with physical disability in patients with multiple sclerosis (MS), new research reports. The study, “Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis,” was published in the Journal of Neuroimaging. Magnetic resonance imaging (MRI) scans are used routinely on MS patients…

A potential biomarker — the ratio of antibody proteins in cerebrospinal fluid at the time of diagnosis — was seen to predict which  multiple sclerosis patients will progress into full-blow disability some five years after being diagnosed in a new study. If confirmed in larger clinical studies, this biomarker could to…

Genentech’s Ocrevus (ocrelizumab) reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows. Researchers will present the results at the American Academy of Neurology’s annual meeting in Los Angeles, April 21-27. The presentation will be titled “Interim Analysis of the…

Multiple sclerosis patients have high levels of a protein called osteopontin in their cerebrospinal fluid and blood, making it a potential tool for diagnosing the disease and predicting its course, a study suggests. The research, “Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis,” was published in the journal PLOS One. Researchers wanted to know if levels of osteopontin in cerebrospinal fluid and blood could be a reliable biomarker for MS. To arrive at answer, they “conducted a systematic review and meta-analysis" of studies that had measured the protein's levels in cerebrospinal fluid and blood "in MS patients and controls." The team searched for studies in three databases — PubMed, Web of Science and Scopus. Out of 27 that met their criteria, they used 22 in the meta-analysis. All four types of MS were represented in the studies — clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS, and primary progressive MS. There were three types of controls in the articles — healthy people, people with non-inflammatory neurological disorders, and people with inflammatory neurological disorders. Researchers' first observation was that all of the MS patients had higher levels of osteopontin than controls. The protein's levels were significantly higher in relapsing-remitting MS patients than in those with clinically isolated syndrome, the group with the lowest osteopontin levels. Levels were similar in the other types of MS. Patients with an active disease had significantly higher levels of the protein in their cerebrospinal fluid than those with a stable disease. The results supported previous studies' findings that osteopontin levels are higher than normal in the cerebrospinal fluid and blood of MS patients, strengthening the notion that it could be used as a biomarker for MS. “Given the fact that OPN [osteopontin] levels are higher during relapses, we think that by monitoring this biomarker,  we might be able to predict the disease course," the team wrote. "We propose that developing drugs modulating OPN concentration may be a new treatment strategy for MS."

Multiple sclerosis patients with central nervous system pain have high levels of a protein known as nerve growth factor in their cerebrospinal fluid, a study shows. The research, “Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain,” was published…

Already an approved treatment for relapsing and primary progressive multiple sclerosis (MS), Ocrevus (ocrelizumab) is still undergoing scrutiny in several clinical trials. Most focus on the drug’s effects in specific patient groups, but one study aims to advance understanding of how Ocrevus works to harness disease. To do so, the open-label Phase 3…